Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
4
Apr 2023
The effects of new inhaled corticosteroid (ICS) treatment on growth in children is a concern that lacks long-term data.1 This study evaluated the safety of one such ICS, fluticasone furoate (FF), and found that over 1 year, FF 50 μg once daily had a minimal effect on growth velocity (n=231) vs placebo (n=226), with no new safety signals.††1 These findings may support the use of FF in children with asthma.
References:
- Bareille P, et al. A multicentre, randomised, double blind, placebo controlled, parallel group study to evaluate the effects of a one-year regimen of orally inhaled fluticasone furoate 50 μg once daily on growth velocity in prepubertal children with asthma. Presented at: European Academy of Allergy and Clinical Immunology (EACCI) Hybrid Congress; 2022, Jul 1–3; Prague, Czech Republic and Online (Abstract no: 001102);
To report an Adverse Event, please contact the toll free line 0800 CALL GSK (0800 2255 475) or send an email
